Ibudilast
生产企业：MediciNova, Inc.
Ibudilast (MN-166) is a CNS-penetrant small molecule with a multi-target mechanism including MIF, PDE, and TLR4 inhibition, under development by MediciNova for amyotrophic lateral sclerosis (ALS) and other neurological indications. It holds Orphan Drug Designation (FDA, EMA) and FDA Fast Track status.
Ibudilast (MN-166) is a CNS-penetrant small molecule with a multi-target mechanism including MIF, PDE, and TLR4 inhibition, under development by MediciNova for amyotrophic lateral sclerosis (ALS) and other neurological indications. It holds Orphan Drug Designation (FDA, EMA) and FDA Fast Track status.
Ibudilast has mechanisms that include anti-inflammatory effects, such as phosphodiesterase inhibition, and neuroprotective effects, such as inhibition of nitric oxide synthesis and reduction in reactive oxygen species.
Ibudilast is in late-stage clinical development for amyotrophic lateral sclerosis (ALS, Phase 3), progressive multiple sclerosis (MS, Phase 3-ready), degenerative cervical myelopathy (DCM, Phase 3), and glioblastoma. It is also in development for Long COVID (Phase 2), chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder. Additionally, ibudilast has been evaluated in patients at risk for developing acute respiratory distress syndrome (ARDS). It is approved in Japan as an anti-inflammatory agent for asthma and cerebrovascular disease.
共 8 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
